SASANLIMAB for Muscle-invasive bladder cancer

Inclusion criteria

• {"criterion_text":"- Patients who sign a written informed consent approved by an IEC for the participation in this trial.\n- Female patients must agree not to breastfeed or donate ovules starting at screening and throughout the study period, and for at least 6 months after the final study drug administration.\n- Male patients with a partner with childbearing potential, or who is pregnant or breastfeeding must agree to abstinence or use a condom plus 1 form of highly effective birth control throughout the study period and for at least 6 months after the final study drug administration.\n- Male patients must not donate sperm starting at screening and throughout the study period, and for at least 6 months after the final study drug administration.\n- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.\n- Patient agrees not to participate in another interventional study while on treatment in the present study.\n- Age ≥ 18 years at the time of consent.\n- ECOG Performance Status of ≤ 1 within 28 days prior to registration (Appendix 6).\n- Histological evidence of localized muscle-invasive urothelial cancer of the bladder (i.e., pT2-T4 / N0 / M0). Histological variants are allowed if the urothelial component is predominantly. Candidate for cystectomy as per treating physician.\n- Absence of metastasis as confirmed by CT or MRI scan of pelvis, abdomen and chest no more than 4 weeks pre-enrolment.\n- Patients candidates to receive neoadjuvant therapy with gemcitabine and cisplatin. Note:MVAC treatment will not be allowed.\n- All subjects must have adequate archival tissue identified at screening (i.e., at least 15 unstained slides or paraffin block). Subjects without archival tissue must be discussed with the Sponsor-investigator.\n- Adequate organ and bone marrow function as defined below: a. Absolute neutrophil count (ANC) ≥ 1.5 x 109/L. b. Hemoglobin (HgB) ≥ 9 g/dL. c. Platelet count ≥ 100 x 109/L. d. Creatinine ≤ 1.5 or creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula). e. Bilirubin ≤ 1.5 × upper limit of normal (ULN). Note: subjects with Gilbert Syndrome, who have total bilirubin < 3.0 mg/dL are eligible. f. Hepatic enzymes Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) < 3 x ULN.\n- Female patients must either: a. Be of nonchildbearing potential: i. Postmenopausal *(defined as at least 1 year without any menses) prior to screening , or ii. Documented surgically sterile (e.g. hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or bilateral tubal occlusion). *Those who are amenorrheic due to an alternative medical cause are not considered postmenopausal and must follow the criteria for childbearing potential subjects. OR b. If of childbearing potential: i. Agree not to try to become pregnant during the study and for at least 6 months after the final study drug administration, ii. And have a negative urine or serum pregnancy test within 7 days prior to Day 1 (females with false positive results and documented verification of negative pregnancy status are eligible for participation), iii. And if heterosexually active, agree to abstinence (if in line with the usual preferred lifestyle of the patient) or consistently use a condom plus 1 form of highly effective birth control (Appendix 7) per locally accepted standards starting at screening and throughout the study period and for a"}

Exclusion criteria

• {"criterion_text":"- Prior treatment with systemic chemotherapy or other approved anticancer treatments for muscle-invasive urothelial cancer of the bladder. Note: In case of prior non muscle-invasive bladder cancer NMIBC, Mitomycin or Bacillus Calmette Guerin (BCG) treatment are allowed.\n- Major surgery less than 28 days prior to the first dose of study treatment.\n- Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A [IgA] dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis.\n- Known or suspected hypersensitivity to active ingredients or excipients of the study drug.\n- Pregnant or breastfeeding.\n- Any serious or uncontrolled medical disorder, psychiatric or social condition that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the subject to receive protocol therapy, or interfere with the interpretation of study results.\n- Another malignancy that is progressing or required active treatment , with the exception of those with a negligible risk of metastasis or death (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer, or ductal carcinoma in situ).\n- Active or prior autoimmune disease that might deteriorate when receiving an immunostimulatory agent. Note: Patients with diabetes type I, vitiligo, psoriasis, or hypothyroid or hyperthyroid disease not requiring immunosuppressive treatment are eligible.\n- Patients that have a diagnosis of immunodeficiency or are receiving systemic steroid therapy or any other form of immunosuppressive therapy within 28 days prior to the first dose of trial treatment, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses (which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid).\n- History of allogeneic organ transplant.\n- Active non-infectious pneumonitis, pulmonary fibrosis, or known history of immune- mediated pneumonitis.\n- Active infection requiring systemic therapy. Patients with active, uncontrolled bacterial, fungal, or viral infection, including HBV, HCV, or known HIV infection.\n- Live attenuated vaccines within 4 weeks prior to the first dose of sasanlimab and through 30 days following the last dose of sasanlimab are not allowed. Note: influenza and SARS-CoV-2 vaccines which are inactivated are allowed.\n- Clinically significant cardiovascular diseases, including any of the following: a. History of acute myocardial infarction, acute coronary syndromes (including unstable angina, coronary artery bypass graft, coronary angioplasty or stenting) ≤6 months prior to start of study treatment. b. Congestive heart failure requiring treatment (New York Heart Association Class ≥2). c. Uncontrolled hypertension, defined as persistent systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg despite optimal therapy. d. History or presence of clinically significant or uncontrolled sustained cardiac arrhythmias (including uncontrolled atrial fibrillation or uncontrolled paroxysmal supraventricular tachycardia). e. History of thromboembolic or cerebrovascular events ≤3 months prior to the first dose of study treatment, including ischemic attacks, cerebrovascular accidents, hemodynamically significant (ie, massive or sub-massive) deep vein thrombosis or pulmonary emboli. Note: Participants with either deep vein thrombosis or pulmonary emboli that do not result in hemodynamic instability are allowed to enroll as long as they are stable, asymptomatic and on stable anticoagulants for at least 2 weeks. Note: Participants with thromboembolic events related to indwelling catheters or other procedures may be enrolled."}

Primary endpoints

• {"endpoint_text":"- The primary endpoint will be the bladder-intact overall survival rate at 12 months after the first dose of sasanlimab. Bladder-intact overall survival is defined as the time from initiation of sasanlimab treatment until death or cystectomy. The primary endpoint will be the percentage of patients who are alive and with no cystectomy at 12 months after the first dose of sasanlimab.","definition_or_measurement_approach":"Bladder-intact overall survival is defined as the time from initiation of sasanlimab treatment until death or cystectomy. The primary endpoint is measured as the percentage of patients who are alive and have not undergone cystectomy at 12 months after the first dose of sasanlimab."}

Secondary endpoints

• {"endpoint_text":"- Clinical response rate, defined as absence of muscle-invasive cancer after cisplatin-based treatment (≤cT1).","definition_or_measurement_approach":"Clinical response rate defined as absence of muscle-invasive cancer after cisplatin-based treatment (≤cT1)."}
• {"endpoint_text":"- Disease-free survival (DFS) according to Section 8.1.","definition_or_measurement_approach":"DFS defined as time from first dose of sasanlimab to first occurrence of DFS event (local recurrence, urinary tract recurrence, distant metastasis, or death) as per protocol Section 8.1."}
• {"endpoint_text":"- Metastasis-free survival (MFS) according to RECIST v1.1 (Appendix 3).","definition_or_measurement_approach":"MFS defined as time from first dose of sasanlimab to first occurrence of distant metastasis of urothelial carcinoma or death; assessed per RECIST v1.1."}
• {"endpoint_text":"- Overall survival (OS).","definition_or_measurement_approach":"OS defined as time from first dose of sasanlimab to death from any cause."}
• {"endpoint_text":"- Health-related quality of life (HRQoL), assessed through the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) version 3 (Appendix 4).","definition_or_measurement_approach":"HRQoL measured using EORTC QLQ-C30 version 3 questionnaire per Appendix 4."}
• {"endpoint_text":"- Frequency and severity of adverse events and treatment-related adverse events (TRAEs) assessed by NCI CTCAE v5.0 (Appendix 5).","definition_or_measurement_approach":"Safety assessed by frequency and severity grading of AEs and TRAEs using NCI CTCAE v5.0."}
• {"endpoint_text":"- Frequency of AEs leading to treatment discontinuation.","definition_or_measurement_approach":"Count and proportion of participants with AEs that result in permanent discontinuation of study treatment."}
• {"endpoint_text":"- Correlation of baseline ctDNA levels with efficacy endpoints.","definition_or_measurement_approach":"Exploratory correlation analyses between baseline circulating tumor DNA (ctDNA) levels and efficacy outcomes."}
• {"endpoint_text":"- Correlation between tumor markers from TURBT biopsy at baseline and benefit of maintenance treatment with sasanlimab.","definition_or_measurement_approach":"Exploratory correlation analyses between baseline tumor markers from TURBT biopsy and clinical benefit from maintenance sasanlimab."}
• {"endpoint_text":"- Changes in ctDNA levels in blood samples throughout the study treatment period.","definition_or_measurement_approach":"Serial ctDNA measurements in blood samples to assess changes over treatment period and their relationship to outcomes."}

Spain

Earliest CTIS Part Ii Submission Date

18-03-2024

Latest Decision Or Authorization Date

12-02-2026

Processing Time Days

696

Number Of Sites

11

Number Of Participants

70

Primary sponsor

Full Name

Fundacion De investigacion De Hm Hospitales

Organisation Type

Hospital/Clinic/Other health care facility

Country Of Registered Address

Spain

Contract research organisations

Name

Mfar Clinical Research S.L.

Responsibilities

codes: 1,10,11,12,3,5,6,7,8

Third parties

• {"country":"Spain","full_name":"Logista Pharma S.A.","duties_or_roles":"code: 14","organisation_type":"Pharmaceutical company"}
• {"country":"Spain","full_name":"Mfar Clinical Research S.L.","duties_or_roles":"codes: 1,10,11,12,3,5,6,7,8","organisation_type":"Laboratory/Research/Testing facility"}